Paul Peter Tak
Paul Peter Tak is a business leader, academic, entrepreneur and clinician who has over 30 years’ experience in medicine as a prominent expert in Immunology, Internal Medicine, and Rheumatology. Paul Peter is currently the President, CEO, and Board Director of Candel Therapeutics, the Co-Founder and Board Director of Sitryx Therapeutics, and Board Director of Levicept and Citryll.
Alongside his industry career, Paul Peter has dedicated much of his life to academia and advancing our understanding in medicine. He has served as Professor of Medicine at the University of Amsterdam and holds numerous honours for his service to medicine, with a special focus on Immunology and Rheumatology.
We are on track for topline data from our fully enrolled phase 3 (intermediate/high-risk; n=711) and phase 2b (low/intermediate risk, active surveillance population; n=187) randomized controlled clinical trials in early, localized prostate cancer in Q4 2024.
#viral #immunotherapy…
Self-experimentation is not necessarily a great idea…, but this case report illustrates the power of viral immunotherapy for solid tumors.
Please join us at the British Society for Immunology meeting on 25-26 Nov 2024 in Cambridge, England.
@britsocimm @CandelTx #viral #immunotherapy #cancer #immunology #ImmuneTherapies24
Sir Ravinder Maini FMedSci FRS and Professor Sir Marc Feldmann AC FMedSci FRS are jointly awarded the Royal Medal 2024 for inventing anti-TNF therapy to treat rheumatoid arthritis, bringing their therapeutic from bench to bedside in one of the biggest success stories in modern…
